Investor Presentation First Nine Months of 2023

82 Investor presentation First nine months of 2023 Rare disease sales decreased by 18%, impacted by a temporary reduction in manufacturing output in rare endocrine disorder DKK billion NovoSevenⓇ and NorditropinⓇ account for ~65% of Rare disease sales DKK billion Global Rare disease franchise 25 25 1% 4% 1% -18% 1% 4% 1% |-18% 20 20 20 15 10 5 0 2020 2021 2022 9M 2023 NovoSevenⓇ Other haemophilia products' Primarily NorditropinⓇ Other Rare disease Growth at CER 1Other haemophilia products primarily consists of Vagifem® and ActivelleⓇ; 9M: 9 months Note: Company reported sales CER: Constant exchange rates; 8 15 7 7 10 5 12 12 13 5 7 2020 2021 2022 9M 2023 IO NAO Growth at CER Novo NordiskⓇ

View entire presentation